In conclusion, our data show that most patients with lymph node metastasis do not have a detectable circulating CD8 antitumor response, but, even in those who do, the proportion of tumor-reactive TIL is significantly lower compared to patients without lymph node metastasis. Here, CD8A is linked to metastatic malignant neoplasm in the lymph nodes.